- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02958670
Imaging Tau Deposition in the Brain of Elderly Subjects (Add-Tau)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single-center exploratory observational clinical study combining cross sectional and longitudinal aspects. It contains 18F-AV-1451-PET as an intervention. The primary objective is to measure tau deposition with 18-F-AV1451-PET based on voxel wise or volume based quantitative assessments and to study the effects of Tau deposition on the organism by identification of factors correlating to the measured tau deposition. Study participants will be followed for up to 8 years.
To date cerebral tau pathology in vivo was only estimated by cerebrospinal fluid (CSF) tau or CSF phospho-tau which precludes a study of topical distribution and interplay with Abeta pathology. 18F-AV-1451 offers the chance to visualize tau pathology and to study effects of tau on brain structure, brain physiology and cognitive function. Ideally, these effects are studied in well characterized individuals in whom other important pathological factors are already known.
We therefore plan to study tau pathology measured by 18F-AV-1451 in subjects with already existing data on cerebral amyloid deposition (11C-Pittsburgh Compound C, Flutemetamol). We will be able to relate tau pathology to past and prospective cognitive performance assessed by a detailed neuro¬psychological examination, and we will be able to investigate whether cerebral tau pathology is reflected by peripheral blood biomarkers. For this purpose we will include elderly subjects with various degrees of cognitive performance (cognitively healthy, mild cognitive impairment, dementia) and various degrees of cerebral amyloid deposition (dichotomized or quantitative). We will also include Frontotemporal Lobar Degeneration (FTLD) cases to study tau effects in neurodegenerative disease in the absence of beta-amyloid.
Our hypotheses are the following:
- We assume that it is possible to identify tau deposition in subjects with and without cerebral Abeta deposition.
- We hypothesize that tau-deposition will be associated with structural and physiological brain changes and that there are synergistic effects of the amount of tau and Abeta pathology on certain brain regions and on cognitive function.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zurich
-
Schlieren, Zurich, Switzerland, 8952
- Institute for Regenerative Medicine (IREM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subject belongs to one of the following groups:
- No cognitive impairment
- Mild cognitive impairment according to Winblad et al., 2004
- Clinical diagnosis of dementia due to Alzheimer's disease compatible with DSM IV criteria or revised NINCDS-ADRDA criteria
- Evidence of neurodegenerative disease other than AD
- Written informed consent approved by the regulatory authorities
- Age ≥ 50 years, women must be without childbearing potential
- Pre-existing PET information (11C-Pittsburgh Compound B, 18F-Flutemetamol) on cerebral amyloid deposition
- German speaking or sufficient knowledge of German language to perform study assessments
- Subject is willing and able to name an informant who can give adequate information on the scales where informant input is required
Exclusion Criteria:
- Evidence for cognitive impairment mainly attributed to a non-neurodegenerative underlying medical condition (e.g. medication, brain tumor, severe heart insufficiency, hepatic encephalopathy)
- Evidence of larger cerebral infarcts, or lacunes in critical memory structures
- Disease or other condition with a potential to interfere with study participation
- Ongoing infection with human immunodeficiency virus (HIV) or any hepatitis virus
- Active, acute or chronic leukemia
- Severe illness likely to cause disability that interferes with study procedures in the following years
- Evidence of acute psychiatric disease (upon clinical decision) which may be a cause of cognitive impairment. Patients with a history of major depression under stable medication may be included. Patients with low dose intake of benzodiazepines may also be included upon clinician's decision
- Previous or current participation in anti-beta-amyloid or anti-tau therapeutic trials
- MR exclusion criteria
- PET exclusion criteria
- Contraindications against venous puncture
- Other condition that might pose a risk to the study subject in the opinion of the investigator
- Exclusion criteria for subproject CSF sampling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-AV-1451-PET
All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
|
Single i.v.
administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal
Time Frame: Baseline measurement
|
Baseline measurement
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Transition from one clinical state to another (e.g. MCI to AD) worsening of clinical function measured as an increase in CDRSOB-score of one
Time Frame: up to two years
|
up to two years
|
Neuropsycholgical test performance
Time Frame: up to two years
|
up to two years
|
Magnetresonance Tomography (MR) readouts
Time Frame: Baseline and two years
|
Baseline and two years
|
Blood and CSF-biomarker-read outs
Time Frame: Baseline and two years
|
Baseline and two years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christoph Hock, Prof.Dr. med, Professor for Biological Psychiatry, Institute for Regenerative Medicine, University of Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH_Nr_2016-01079_V10.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on 18F-AV-1451 (Tau-PET tracer)
-
Duke UniversityWithdrawnTraumatic Brain Injury | Posttraumatic Stress Disorder | Alzheimer DementiaUnited States
-
Northwestern UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia With Suspected Alzheimer's DiseaseUnited States
-
University of PennsylvaniaCompletedLogopenic Progressive Aphasia | Posterior Cortical Atrophy (PCA) | Alzheimer's Disease, Early OnsetUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States
-
Neil M Rofsky, MD, MHACompletedAlzheimer Disease | Cognitive DeclineUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States
-
University of Southern CaliforniaAvid Radiopharmaceuticals; Alzheimer's Therapeutic Research Institute; Alzheimer...CompletedCognition DisordersUnited States
-
Avid RadiopharmaceuticalsCompleted
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States